RYTM
Rhythm Pharmaceuticals Announces FDA Approval of Imcivree® (Setmelanotide) for Patients as Young as 2 Years Old
时间：2024-12-21 03:15:00 市场： 美股 综合
Rhythm Pharmaceuticals Announces Five Presentations at Espe 2024, Including New Real-World Data in Pediatric Patients With Acquired or Congenital Hypothalamic Obesity Treated With Setmelanotide
时间：2024-11-18 20:00:00 市场： 美股 综合
Rhythm Pharmaceuticals Inc : TD Cowen Raises Target Price to $65 From $55
时间：2024-11-06 14:03:34 市场： 美股 综合